A Phase 3 interventional study of Levodopa-Carbidopa Intestinal Gel and Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J) in Advanced Parkinson's Disease, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2021-07-16.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing levodopa in Parkinson Disease — 3 open to participants now, 3 under way, none of them phase 3. Levodopa · Parkinson Disease.
Among the 51 studies testing levodopa in Parkinson Disease, this one is the 31st largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2013, is one of 12 in phase 3, and was the 30th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →3 of the 51 studies testing levodopa in Parkinson Disease are open now, in 2 countries. Recruiting first, the newest first:
Second Affiliated Hospital of Soochow University · Sites in China
Ages 30–80
Emory University · Sites in United States
Ages 45–75 · Healthy volunteers
Beth Israel Deaconess Medical Center · Sites in United States
By country, each count listing its studies:
Levodopa: first FDA approval 1970 (LARODOPA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 11 · Phase 3 12 · Phase 4 17
First in 1998; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is close to the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 56 across the 50 interventional studies. Of the 45 that completed or were terminated, 18 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 51 have an industry lead sponsor. The 10 most frequent:
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
44 studies in Parkinson Disease by AbbVie: 6 open now, 9 under way, none of them phase 3. Of 33 finished, 18 (55%) have results posted.
Among the 44 studies in Parkinson Disease by AbbVie, this one is the 15th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2013, is one of 16 in phase 3, and was the 6th registered.
AbbVie’s Parkinson Disease studies by the year they started, since 2006.
1 of the studies testing levodopa in Parkinson Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06234995Emory UniversityCortical Electrophysiology of Response Inhibition in Parkinson's Disease | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 51 studies testing levodopa in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 44 in Parkinson Disease:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate change in non-motor symptoms from baseline to Week 12 as measured by the Non-Motor Symptom Scale total score.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants had the PEG-J tube placement procedure performed on Study Day 1 and, at the discretion of the investigator, began initiation and titration of LCIG infusion. Dosing was determined individually. The starting total daily dose of LCIG was based solely on the daily dose of the oral levodopa taken immediately prior to Study Day 1 and was adjusted to obtain the optimal clinical response for the individual participant. Participants received treatment for up to 60 weeks; participants who completed their Week 60 visit before LCIG was commercially available had the option to extend their LCIG therapy, if in the opinion of the investigator, the participant would benefit from continued LCIG treatment.
Drug: Levodopa-Carbidopa Intestinal Gel · Procedure: Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J) · Drug: Levodopa-carbidopa Immediate Release (LC-IR) Tablets
Drug pages: Levodopa · Carbidopa
Levodopa-carbidopa intestinal gel (LCIG) for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa monohydrate (5 mg/mL) in an aqueous gel, administered continuously by a portable pump via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube. The rate of LCIG infusion was expected to be within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances over a period of 16 consecutive hours.
Also known as: Duopa, Carbidopa-levodopa enteral suspension (CLES)
After LCIG initiation, participants could take prescribed oral levodopa-carbidopa immediate or continuous release (i.e., oral LC prescribed by the investigator) for nighttime use.
Change From Baseline to Week 12 in the Non-Motor Symptom Scale (NMSS) Total Score
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; the total score is obtained by summing the item scores. The NMSS total score ranges from 0 to 360 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
Time frame: Baseline and Week 12
Number of Participants Who Used Healthcare Resources During the First 4 Weeks
Use of healthcare resources was assessed by the investigator using the Health Resource Utilization Questionnaire (HRUQ), a questionnaire developed by the Sponsor regarding the use of healthcare resources due to the participant's Parkinson's disease. The Week 4 version of the questionnaire addressed the following questions during the first four weeks after the PEG-J procedure: 1. Has the subject had a visit to an emergency room? 2. Has the subject had a visit to an urgent care? 3. Has the subject had an outpatient visit to a neurologist? 4. Has the subject had an outpatient visit to a gastroenterologist, surgeon, or interventional radiologist? 5. Has the subject had an outpatient visit to a primary care physician? 6. Has the subject called the nursing support line? 7. Has the subject called a physician?
Time frame: Weeks 1-4
Number of Participants With Adverse Events
Adverse events (AEs) related to treatment are those the investigator determined as having a reasonable possibility being related to study drug based on evidence to suggest a causal relationship between the study drug and the adverse event. A severe AE was defined as an adverse event that caused considerable interference with the participant's usual activities and might be incapacitating or life-threatening. Serious AEs were defined as those that were life-threatening or resulted in death, hospitalization or prolongation of hospitalization, a congenital anomaly, persistent or significant disability/incapacity, or important medical events requiring medical or surgical intervention to prevent a serious outcome.
Time frame: Weeks 1-4 and Overall (from Week 1 through 30 days after the end of the LCIG Treatment Period; median duration of LCIG device exposure was 428 days)
Number of Participants Who Used Healthcare Resources Through Week 60
Use of healthcare resources was assessed by the investigator using the Health Resource Utilization Questionnaire (HRUQ), a questionnaire developed by the Sponsor regarding the use of healthcare resources due to the participant's Parkinson's disease. The standard version of the questionnaire addressed the following questions over the last 3 months: 1. Has the subject had a visit to an emergency room? 2. Has the subject had an outpatient visit to any of the following healthcare providers? 3. Has the subject been visited in his or her place of residence by a health care professional? 4. Has the subject received assistance from either of the following for their Parkinson's disease in their home? 5. Has the subject needed to contact either of the following for immediate assistance related to their Parkinson's disease? 6. Have family members or friends had to miss any paid work due to the subject's Parkinson's disease? 7. Has the subject fallen during the past month?
Time frame: Week 60
Change From Baseline to Week 60 in the Non-Motor Symptom Scale (NMSS) Total Score
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; the total score is obtained by summing the item scores. The NMSS total score ranges from 0 to 360 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
Time frame: Baseline and Week 60
Change From Baseline in NMSS Cardiovascular Domain Score
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS cardiovascular including falls domain score ranges from 0 to 24 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Sleep/Fatigue Domain Score
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS sleep/fatigue domain score ranges from 0 to 48 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Mood/Cognition Domain Score
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS mood/cognition domain score ranges from 0 to 72 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Perceptual Problems/Hallucinations Domain Score
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS perceptual problems/hallucinations domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Attention/Memory Domain Score
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS attention/memory domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Gastrointestinal Tract Domain Score
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS gastrointestinal tract domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Urinary Domain Score
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS urinary domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Sexual Function Domain Score
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS sexual function domain score ranges from 0 to 24 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in NMSS Miscellaneous Domain Score
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS miscellaneous domain score ranges from 0 to 48 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in Mean Daily Normalized "Off" Time Based on Parkinson's Disease Diary
The Parkinson's Disease Diary was completed by the participant for 3 consecutive days prior to each visit for the full 24 hours of each day. Participants recorded whether they had been "On," "Off," or "Asleep" and the severity of their dyskinesias (troublesome or not troublesome) for each 30-minute period during their normal waking time and upon awakening from time asleep. "Off" time was defined as time when medication has worn off and was no longer providing benefit with regard to mobility, slowness, and stiffness. Parkinson's Disease Diary times were normalized to a 16-hour waking time to account for variation in participants' sleep time. Normalized PD Diary times at a given visit were calculated as the average normalized time from the PD Diary for the 3 days prior to the visit.
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in Mean Daily Normalized "On" Time Without Troublesome Dyskinesia Based on PD Diary
The PD Diary was completed by the participant for 3 consecutive days prior to each visit. Participants recorded whether they had been "On," "Off," or "Asleep" and the severity of their dyskinesias (troublesome or not troublesome) for each 30-minute period during their normal waking time and upon awakening from sleep. "On" was defined as time when medication was providing benefit with regard to mobility, slowness, and stiffness. "On" time without troublesome dyskinesia is a composite of "On" time without dyskinesia (involuntary twisting, turning movements which are an effect of medication) plus "On" time with non-troublesome dyskinesia (dyskinesia that does not interfere with function or cause meaningful discomfort). PD Diary times were normalized to a 16-hour waking time to account for variation in participants' sleep time. Normalized PD Diary times at a given visit were calculated as the average normalized time from the PD Diary for the 3 days prior to the visit.
Time frame: Baseline and Week 12 and Week 60
Change From Baseline for Unified Parkinson's Disease Rating Scale (UPDRS) Total Score
The Unified Parkinson's Disease Rating Scale (UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The Total UPDRS score includes 31 items contributing to three subscales: (I) Mentation, Behavior, and Mood; (II) Activities of Daily Living; and (III) Motor Examination. Each question is answered on a scale from 0 (None) to 4 (Severe); Some questions require multiple grades assigned to each extremity. The UPDRS Total score was computed as the sum of these 3 UPDRS subscales and ranged from 0 to 176, with 176 representing the worst (total) disability, and 0 no disability.
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in UPDRS Part I: Mentation, Behavior, and Mood Score
The Unified Parkinson's Disease Rating Scale (UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The mentation, behavior, and mood score includes 4 items addressing intellectual impairment, thought disorder, motivation/initiative, and depression. Each question is answered on a scale from 0 (None) to 4 (Severe). The UPDRS Part I: mentation, behavior, and mood score was computed as the sum of these items and ranged from 0 (not affected) to 16 (most severely affected).
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in UPDRS Part II: Activities of Daily Living (ADL) Score
The Unified Parkinson's Disease Rating Scale (UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The activities of daily living score includes 13 items addressing speech, salivation, swallowing, handwriting, cutting food, dressing, hygiene, turning in bed, falling, freezing, walking, tremor, and sensory complaints. Each question is answered on a scale from 0 (Normal) to 4 (Severe). The UPDRS Part II: activities of daily living score was computed as the sum of these items and ranged from 0 (not affected) to 52 (most severely affected).
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in UPDRS Part III: Motor Examination Score
The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The motor examination score includes 17 items addressing speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability, and body bradykinesia. Each question is answered on a scale from 0 (Normal) to 4 (Severe), some items include multiple grades for each extremity. The UPDRS Part III: motor examination score was computed as the sum of these items and ranged from 0 (not affected) to 108 (most severely affected).
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in UPDRS Part IV: Complications of Therapy Score
The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The complications of therapy section includes 11 items addressing dyskinesia duration, disability, and pain, early morning dystonia, "offs"-predictable, "offs"-unpredictable, "offs"-sudden, "offs"-duration, anorexia-nausea-vomiting, sleep disturbance, and symptomatic orthostasis. Four questions are answered on a scale from 0 (Normal) to 4 (Severe) and seven on a binary scale where 0=No and 1=Yes. The UPDRS Part IV: complications of therapy score was computed as the sum of these items and ranged from 0 (not affected) to 23 (most severely affected).
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in UPDRS Dyskinesia Items Score
The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The dyskinesia items score includes questions 32, 33 and 34 from the complications of therapy section of the UPDRS which address dyskinesia duration, disability, and pain. Each question was answered on a scale from 0 (Normal) to 4 (Severe); the UPDRS dyskinesia items score was computed as the sum of these items and ranged from 0 (not affected) to 12 (most severely affected).
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in UPDRS Part V: Modified Hoehn and Yahr Staging Score
The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The modified Hoehn and Yahr scale is as follows: * Stage 0: No signs of disease * Stage 1.0: Symptoms are very mild; unilateral involvement only * Stage 1.5: Unilateral and axial involvement * Stage 2: Bilateral involvement without impairment of balance * Stage 2.5: Mild bilateral disease with recovery on pull test * Stage 3: Mild to moderate bilateral disease; some postural instability; physically independent * Stage 4: Severe disability; still able to walk or stand unassisted * Stage 5: Wheelchair bound or bedridden unless aided
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in Parkinson's Disease Questionnaire-39 Item (PDQ-39) Summary Index
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). The PDQ-39 Summary Index (PDQ-SI) is the sum of all answers divided by the highest score possible (i.e., number of answers multiplied by 4) which is multiplied by 100 to put the score on a 0 - 100 scale where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Mobility Domain Score
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Activities of Daily Living Domain Score
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Emotional Well-Being Domain Score
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Stigma Domain Score
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Social Support Domain Score
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Cognition Domain Score
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Communication Domain Score
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
Time frame: Baseline and Week 12 and Week 60
Change From Baseline in PDQ-39 Bodily Discomfort Domain Score
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
Time frame: Baseline and Week 12 and Week 60
Percentage of Participants With a Patient Global Impression of Change (PGIC) Response of Improved
The PGIC is a 7-point response scale. Participants were asked to rate their change in status using the following 7-point scale: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. The responses of "Very much improved," "Much improved" and "Minimally improved" on the PGIC were used to define responders.
Time frame: Week 12 and Week 60
Treatment Satisfaction Questionnaire Scores
The Treatment Satisfaction Questionnaire (TSQ) is a single item instrument developed by the Sponsor on which the participant indicated their level of satisfaction or dissatisfaction with their PD treatment. The responses are recorded on a Likert-type scale (Very Satisfied, Satisfied, Somewhat Satisfied, Somewhat Dissatisfied, Dissatisfied, Very Dissatisfied).
Time frame: Week 12 and Week 60
Change From Baseline in Health-related Productivity
The Health-Related Productivity Questionnaire (HRPQ) is a generic measure of the impact of disease on the ability of the participant to be productive at paid employment or at performance of household chores. Questions inquire about the amount of time they were scheduled/planned to work, the number of the scheduled/planned hours they were able to work and their ability to be productive for the hours of work they did perform. Absenteeism: Number of hours not worked due to PD or it's treatments; Presenteeism: Number of hours of lost productivity while at work due to PD or it's treatments; Total hours lost: Number of hours lost due to absenteeism and presenteeism
Time frame: Baseline, Week 12 and Week 60
Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Spatial Working Memory Between Errors Score at Week 12
CANTAB is a computer-based test of the participant's ability to retain spatial information and to manipulate remembered items in working memory. The Spatial Working Memory module requires that subjects find a blue token in a series of displayed boxes and use these to fill up an empty column, while not returning to boxes where a blue token has been previously found. The between errors score is the number of times the participant revisited a box in which a token was previously found; errors are calculated for 4-, 6-, and 8-box trials. Higher numbers indicate poorer performance.
Time frame: Baseline and Week 12
Change From Baseline in CANTAB Spatial Working Memory Strategy Score at Week 12
CANTAB is a computer-based test of the participant's ability to retain spatial information and to manipulate remembered items in working memory. The Spatial Working Memory module requires that subjects find a blue token in a series of displayed boxes and use these to fill up an empty column, while not returning to boxes where a blue token has been previously found. The Strategy score represents the number of times a participant begins a search with the same box for 6- and 8-box problems. Minimum score is 8 and maximum score is 56. Higher numbers indicate poorer performance.
Time frame: Baseline and Week 12
Change From Baseline in Controlled Oral Word Association Test (COWAT) Verbal Fluency Scores at Week 60
Letter fluency was assessed using a paper and pen test, in which participants were asked to generate as many words as possible in 60 seconds, starting with the letters F, A, or S. The COWAT All Letters score is the number of words recalled in all post-baseline assessments, regardless of letter used. The COWAT Baseline Letter score is the number of words recalled in post-baseline assessments that used the same letter as at Baseline.
Time frame: Baseline and Week 60
This study was conducted at 12 sites in the United States that specialized in movement disorders. Participants were levodopa-responsive with advanced Parkinson's disease (PD) and persistent motor fluctuations despite attempts to optimize treatment with oral levodopa-carbidopa and other available anti-PD medications.
| Milestone | Levodopa-Carbidopa Intestinal Gel (LCIG) |
|---|---|
| Started | 39 |
| Received lcig | 38 |
| Completed | 28 |
| Not completed | 11 |
| Withdrew: Adverse event | 3 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Lack of efficacy | 3 |
| Withdrew: Unable to complete peg placement | 1 |
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; the total score is obtained by summing the item scores. The NMSS total score ranges from 0 to 360 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Change From Baseline to Week 12 in the Non-Motor Symptom Scale (NMSS) Total Score | -17.6 ± 3.60 |
Use of healthcare resources was assessed by the investigator using the Health Resource Utilization Questionnaire (HRUQ), a questionnaire developed by the Sponsor regarding the use of healthcare resources due to the participant's Parkinson's disease. The Week 4 version of the questionnaire addressed the following questions during the first four weeks after the PEG-J procedure: 1. Has the subject had a visit to an emergency room? 2. Has the subject had a visit to an urgent care? 3. Has the subject had an outpatient visit to a neurologist? 4. Has the subject had an outpatient visit to a gastroenterologist, surgeon, or interventional radiologist? 5. Has the subject had an outpatient visit to a primary care physician? 6. Has the subject called the nursing support line? 7. Has the subject called a physician?
| Participants | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Q1. Emergency Room Visit | 3 |
| Q2. Urgent Care Visit | 0 |
| Q3. Neurologist Visit | 6 |
| Q4. Gastroenterologist, Surgeon, Radiologist Visit | 11 |
| Q5. Primary Care Physician Visit | 8 |
| Q6. Called Nursing Support Line | 9 |
| Q7. Called Physician | 13 |
Adverse events (AEs) related to treatment are those the investigator determined as having a reasonable possibility being related to study drug based on evidence to suggest a causal relationship between the study drug and the adverse event. A severe AE was defined as an adverse event that caused considerable interference with the participant's usual activities and might be incapacitating or life-threatening. Serious AEs were defined as those that were life-threatening or resulted in death, hospitalization or prolongation of hospitalization, a congenital anomaly, persistent or significant disability/incapacity, or important medical events requiring medical or surgical intervention to prevent a serious outcome.
| Participants | Week 1-4 | Overall |
|---|---|---|
| Any adverse event | 28 | 37 |
| AE related to LCIG | 26 | 35 |
| AE related to oral LC | 4 | 11 |
| Severe adverse event | 1 | 5 |
| Serious adverse event | 3 | 8 |
| AE leading to premature discontinuation | 1 | 5 |
| Gastrointestinal (GI) adverse event | 22 | 28 |
| Adverse event other than GI | 21 | 37 |
| Fatal adverse event | 0 | 1 |
Use of healthcare resources was assessed by the investigator using the Health Resource Utilization Questionnaire (HRUQ), a questionnaire developed by the Sponsor regarding the use of healthcare resources due to the participant's Parkinson's disease. The standard version of the questionnaire addressed the following questions over the last 3 months: 1. Has the subject had a visit to an emergency room? 2. Has the subject had an outpatient visit to any of the following healthcare providers? 3. Has the subject been visited in his or her place of residence by a health care professional? 4. Has the subject received assistance from either of the following for their Parkinson's disease in their home? 5. Has the subject needed to contact either of the following for immediate assistance related to their Parkinson's disease? 6. Have family members or friends had to miss any paid work due to the subject's Parkinson's disease? 7. Has the subject fallen during the past month?
| Participants | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Q1. Emergency Room Visit | 1 |
| Q2. Visit to Primary Care Physician | 18 |
| Q2. Visit to Gastroenterologist | 3 |
| Q2. Visit to Interventional Radiologist | 1 |
| Q2. Visit to Surgeon | 1 |
| Q2. Visit to Cardiologist | 1 |
| Q2. Visit to Endocrinologist | 0 |
| Q2. Visit to Immunologist | 0 |
| Q2. Visit to Internist | 1 |
| Q2. Visit to Psychiatrist | 0 |
| Q2. Visit to Urologist | 2 |
| Q2. Visit to Psychologist | 1 |
| Q2. Visit to Social Worker | 2 |
| Q2. Visit to Other Healthcare Provider | 10 |
| Q3. Visited by Physician | 0 |
| Q3. Visited by Nurse or Nurse Practitioner | 1 |
| Q3. Visited by Physical or Occupational Therapist | 0 |
| Q4. Received Unpaid Care From Family/Friend | 10 |
| Q4. Received Care From Paid Caregiver | 2 |
| Q5. Called 911 | 0 |
| Q5. Called Family/Friend | 1 |
| Q6. Family/Friends Missed Work | 2 |
| Q7. Fall During Past Month | 10 |
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; the total score is obtained by summing the item scores. The NMSS total score ranges from 0 to 360 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Change From Baseline to Week 60 in the Non-Motor Symptom Scale (NMSS) Total Score | -11.8 ± 3.95 |
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS cardiovascular including falls domain score ranges from 0 to 24 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -0.2 ± 0.37 |
| Week 60 | 0.5 ± 0.41 |
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS sleep/fatigue domain score ranges from 0 to 48 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -6.0 ± 1.17 |
| Week 60 | -5.4 ± 1.29 |
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS mood/cognition domain score ranges from 0 to 72 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | 0.0 ± 1.12 |
| Week 60 | 0.5 ± 1.24 |
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS perceptual problems/hallucinations domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -0.5 ± 0.38 |
| Week 60 | 0.4 ± 0.43 |
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS attention/memory domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -2.1 ± 0.80 |
| Week 60 | -2.2 ± 0.87 |
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS gastrointestinal tract domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -2.0 ± 0.60 |
| Week 60 | -1.9 ± 0.67 |
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS urinary domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -2.2 ± 1.07 |
| Week 60 | 0.1 ± 1.19 |
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS sexual function domain score ranges from 0 to 24 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -1.8 ± 0.42 |
| Week 60 | -1.1 ± 0.47 |
The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS miscellaneous domain score ranges from 0 to 48 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -3.4 ± 1.00 |
| Week 60 | -3.4 ± 1.11 |
The Parkinson's Disease Diary was completed by the participant for 3 consecutive days prior to each visit for the full 24 hours of each day. Participants recorded whether they had been "On," "Off," or "Asleep" and the severity of their dyskinesias (troublesome or not troublesome) for each 30-minute period during their normal waking time and upon awakening from time asleep. "Off" time was defined as time when medication has worn off and was no longer providing benefit with regard to mobility, slowness, and stiffness. Parkinson's Disease Diary times were normalized to a 16-hour waking time to account for variation in participants' sleep time. Normalized PD Diary times at a given visit were calculated as the average normalized time from the PD Diary for the 3 days prior to the visit.
| hours | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -4.1 ± 0.39 |
| Week 60 | -4.9 ± 0.48 |
The PD Diary was completed by the participant for 3 consecutive days prior to each visit. Participants recorded whether they had been "On," "Off," or "Asleep" and the severity of their dyskinesias (troublesome or not troublesome) for each 30-minute period during their normal waking time and upon awakening from sleep. "On" was defined as time when medication was providing benefit with regard to mobility, slowness, and stiffness. "On" time without troublesome dyskinesia is a composite of "On" time without dyskinesia (involuntary twisting, turning movements which are an effect of medication) plus "On" time with non-troublesome dyskinesia (dyskinesia that does not interfere with function or cause meaningful discomfort). PD Diary times were normalized to a 16-hour waking time to account for variation in participants' sleep time. Normalized PD Diary times at a given visit were calculated as the average normalized time from the PD Diary for the 3 days prior to the visit.
| hours | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | 3.7 ± 0.48 |
| Week 60 | 4.3 ± 0.58 |
The Unified Parkinson's Disease Rating Scale (UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The Total UPDRS score includes 31 items contributing to three subscales: (I) Mentation, Behavior, and Mood; (II) Activities of Daily Living; and (III) Motor Examination. Each question is answered on a scale from 0 (None) to 4 (Severe); Some questions require multiple grades assigned to each extremity. The UPDRS Total score was computed as the sum of these 3 UPDRS subscales and ranged from 0 to 176, with 176 representing the worst (total) disability, and 0 no disability.
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -11.4 ± 1.67 |
| Week 60 | -7.7 ± 2.26 |
The Unified Parkinson's Disease Rating Scale (UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The mentation, behavior, and mood score includes 4 items addressing intellectual impairment, thought disorder, motivation/initiative, and depression. Each question is answered on a scale from 0 (None) to 4 (Severe). The UPDRS Part I: mentation, behavior, and mood score was computed as the sum of these items and ranged from 0 (not affected) to 16 (most severely affected).
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -0.3 ± 0.31 |
| Week 60 | -0.1 ± 0.26 |
The Unified Parkinson's Disease Rating Scale (UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The activities of daily living score includes 13 items addressing speech, salivation, swallowing, handwriting, cutting food, dressing, hygiene, turning in bed, falling, freezing, walking, tremor, and sensory complaints. Each question is answered on a scale from 0 (Normal) to 4 (Severe). The UPDRS Part II: activities of daily living score was computed as the sum of these items and ranged from 0 (not affected) to 52 (most severely affected).
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -5.5 ± 0.89 |
| Week 60 | -4.7 ± 0.92 |
The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The motor examination score includes 17 items addressing speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability, and body bradykinesia. Each question is answered on a scale from 0 (Normal) to 4 (Severe), some items include multiple grades for each extremity. The UPDRS Part III: motor examination score was computed as the sum of these items and ranged from 0 (not affected) to 108 (most severely affected).
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -5.6 ± 1.19 |
| Week 60 | -3.6 ± 1.49 |
The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The complications of therapy section includes 11 items addressing dyskinesia duration, disability, and pain, early morning dystonia, "offs"-predictable, "offs"-unpredictable, "offs"-sudden, "offs"-duration, anorexia-nausea-vomiting, sleep disturbance, and symptomatic orthostasis. Four questions are answered on a scale from 0 (Normal) to 4 (Severe) and seven on a binary scale where 0=No and 1=Yes. The UPDRS Part IV: complications of therapy score was computed as the sum of these items and ranged from 0 (not affected) to 23 (most severely affected).
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -3.5 ± 0.44 |
| Week 60 | -2.9 ± 0.57 |
The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The dyskinesia items score includes questions 32, 33 and 34 from the complications of therapy section of the UPDRS which address dyskinesia duration, disability, and pain. Each question was answered on a scale from 0 (Normal) to 4 (Severe); the UPDRS dyskinesia items score was computed as the sum of these items and ranged from 0 (not affected) to 12 (most severely affected).
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -1.1 ± 0.28 |
| Week 60 | -0.6 ± 0.36 |
The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The modified Hoehn and Yahr scale is as follows: * Stage 0: No signs of disease * Stage 1.0: Symptoms are very mild; unilateral involvement only * Stage 1.5: Unilateral and axial involvement * Stage 2: Bilateral involvement without impairment of balance * Stage 2.5: Mild bilateral disease with recovery on pull test * Stage 3: Mild to moderate bilateral disease; some postural instability; physically independent * Stage 4: Severe disability; still able to walk or stand unassisted * Stage 5: Wheelchair bound or bedridden unless aided
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -0.2 ± 0.10 |
| Week 60 | -0.2 ± 0.12 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). The PDQ-39 Summary Index (PDQ-SI) is the sum of all answers divided by the highest score possible (i.e., number of answers multiplied by 4) which is multiplied by 100 to put the score on a 0 - 100 scale where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -11.2 ± 2.75 |
| Week 60 | -10.2 ± 2.63 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -18.5 ± 4.39 |
| Week 60 | -19.4 ± 4.21 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -12.1 ± 4.43 |
| Week 60 | -11.9 ± 4.23 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -4.9 ± 3.14 |
| Week 60 | -6.6 ± 3.74 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -9.5 ± 2.38 |
| Week 60 | -5.4 ± 3.01 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | 1.6 ± 2.62 |
| Week 60 | 3.3 ± 2.95 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -8.4 ± 2.23 |
| Week 60 | -7.3 ± 2.00 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -13.0 ± 3.24 |
| Week 60 | -10.8 ± 2.59 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | -9.6 ± 4.40 |
| Week 60 | -3.8 ± 3.65 |
The PGIC is a 7-point response scale. Participants were asked to rate their change in status using the following 7-point scale: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. The responses of "Very much improved," "Much improved" and "Minimally improved" on the PGIC were used to define responders.
| percentage of participants | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Week 12 | 78.9 |
| Week 60 | 71.1 |
The Treatment Satisfaction Questionnaire (TSQ) is a single item instrument developed by the Sponsor on which the participant indicated their level of satisfaction or dissatisfaction with their PD treatment. The responses are recorded on a Likert-type scale (Very Satisfied, Satisfied, Somewhat Satisfied, Somewhat Dissatisfied, Dissatisfied, Very Dissatisfied).
| Participants | Week 12 | Week 60 |
|---|---|---|
| Very satisfied | 15 | 14 |
| Satisfied | 14 | 9 |
| Somewhat satisfied | 4 | 3 |
| Somewhat dissatisfied | 1 | 1 |
| Dissatisfied | 1 | 0 |
| Very dissatisfied | 0 | 1 |
| Missing | 3 | 10 |
The Health-Related Productivity Questionnaire (HRPQ) is a generic measure of the impact of disease on the ability of the participant to be productive at paid employment or at performance of household chores. Questions inquire about the amount of time they were scheduled/planned to work, the number of the scheduled/planned hours they were able to work and their ability to be productive for the hours of work they did perform. Absenteeism: Number of hours not worked due to PD or it's treatments; Presenteeism: Number of hours of lost productivity while at work due to PD or it's treatments; Total hours lost: Number of hours lost due to absenteeism and presenteeism
| hours | Week 12 | Week 60 |
|---|---|---|
| Workplace Work Lost - Absenteeism | -2.1 ± 4.63 | -5.2 ± 6.27 |
| Household Work Lost - Absenteeism | -3.5 ± 11.19 | -1.9 ± 8.38 |
| Workplace Work Lost - Presenteeism | -0.8 ± 13.04 | -0.3 ± 3.87 |
| Household Work Lost - Presenteeism | -1.8 ± 6.42 | -1.9 ± 5.42 |
| Total Workplace Work Lost | -3.0 ± 8.87 | -5.5 ± 4.50 |
| Total Household Work Lost | -5.3 ± 15.69 | -3.8 ± 11.26 |
CANTAB is a computer-based test of the participant's ability to retain spatial information and to manipulate remembered items in working memory. The Spatial Working Memory module requires that subjects find a blue token in a series of displayed boxes and use these to fill up an empty column, while not returning to boxes where a blue token has been previously found. The between errors score is the number of times the participant revisited a box in which a token was previously found; errors are calculated for 4-, 6-, and 8-box trials. Higher numbers indicate poorer performance.
| errors | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Spatial Working Memory Between Errors Score at Week 12 | -0.6 ± 7.73 |
CANTAB is a computer-based test of the participant's ability to retain spatial information and to manipulate remembered items in working memory. The Spatial Working Memory module requires that subjects find a blue token in a series of displayed boxes and use these to fill up an empty column, while not returning to boxes where a blue token has been previously found. The Strategy score represents the number of times a participant begins a search with the same box for 6- and 8-box problems. Minimum score is 8 and maximum score is 56. Higher numbers indicate poorer performance.
| units on a scale | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Change From Baseline in CANTAB Spatial Working Memory Strategy Score at Week 12 | 0.8 ± 2.31 |
Letter fluency was assessed using a paper and pen test, in which participants were asked to generate as many words as possible in 60 seconds, starting with the letters F, A, or S. The COWAT All Letters score is the number of words recalled in all post-baseline assessments, regardless of letter used. The COWAT Baseline Letter score is the number of words recalled in post-baseline assessments that used the same letter as at Baseline.
| words | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| All Letters Score | -0.5 ± 4.80 |
| Baseline Letter Score | -1.8 ± 4.03 |
Collected over Weeks 1-4 and Overall (from Week 1 through 30 days after the end of the LCIG Treatment Period; median duration of LCIG device exposure was 428 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levodopa-Carbidopa Intestinal Gel | — | 8/39 (20.5%) | 36/39 (92.3%) |
| Event | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| ATRIAL FIBRILLATIONCardiac disorders | 1/39 |
| CARDIAC FAILURE CONGESTIVECardiac disorders | 1/39 |
| INTERNAL HERNIAGastrointestinal disorders | 1/39 |
| PERITONITISInfections and infestations | 1/39 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 1/39 |
| BASAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/39 |
| RADICULOPATHYNervous system disorders | 1/39 |
| SEDATIONNervous system disorders | 1/39 |
| ANXIETYPsychiatric disorders | 1/39 |
| MAJOR DEPRESSIONPsychiatric disorders | 1/39 |
| Event | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| PROCEDURAL PAINInjury, poisoning and procedural complications | 13/39 |
| STOMA SITE INFECTIONInfections and infestations | 11/39 |
| STOMA SITE PAINInjury, poisoning and procedural complications | 9/39 |
| STOMA SITE ERYTHEMAInjury, poisoning and procedural complications | 8/39 |
| FALLInjury, poisoning and procedural complications | 7/39 |
| WEIGHT DECREASEDInvestigations | 7/39 |
| ANXIETYPsychiatric disorders | 7/39 |
| URINARY TRACT INFECTIONInfections and infestations | 6/39 |
| ORTHOSTATIC HYPOTENSIONVascular disorders | 5/39 |
| FLATULENCEGastrointestinal disorders | 4/39 |
| Age, Continuous(years) | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Mean | 64.3 ± 10.23 |
| Age, Customized(Participants) | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| < 65 years | 17 |
| ≥ 65 years | 22 |
| Sex: Female, Male(Participants) | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Female | 16 |
| Male | 23 |
| Race/Ethnicity, Customized(Participants) | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| White | 36 |
| Black or African American | 1 |
| Asian | 2 |
| American Indian or Alaska Native | 0 |
| Native Hawaiian or other Pacific Islander | 0 |
| Race/Ethnicity, Customized(Participants) | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 37 |
| Duration of PD(years) | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Mean | 11.5 ± 5.34 |
| PD Symptoms Present(Participants) | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Bradykinesia | 37 |
| Muscular rigidity | 33 |
| Resting tremor | 25 |
| Postural instability | 22 |
| Non-Motor Symptoms Scale (NMSS) Total Score(units on a scale) | Levodopa-Carbidopa Intestinal Gel |
|---|---|
| Mean | 48.3 ± 35.63 |
No study locations are listed for this record.
The record gives a start of Mar 2013, a primary completion of Mar 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2017, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Levodopa · Carbidopa
AbbVie (prior sponsor, Abbott) →